Loading...
Limited treatment options are available for advanced-stage cutaneous T-cell lymphoma (CTCL). From 1999 to 2014, the fusion protein denileukin diftitox (DD) was available in the U.S. for CTCL treatment but then was withdrawn and reformulated to improve purity and bioactivity. Investigators now report on the reformulation, DD-cxdl, which, like its predecessor, links diphtheria toxin fragments to interleukin 2 (IL-2) and then binds to tumor cells expressing the IL-2 receptor, with subsequent intracellular toxin release and tumor-cell death.
In this multicenter, phase 3, single-arm registrational trial, 69 patients with relapsed or refractory stage IA–IIIB mycosis fungoides or Sézary syndrome and at least one prior systemic therapy received DD-c…